Brief report: Four-year survival with durvalumab after chemoradiotherapy in Stage III NSCLC - an update from the PACIFIC trial.

Faivre-Finn, Corinne; Vicente, David; Kurata, Takayasu; Planchard, David; Paz-Ares, Luis; Vansteenkiste, Johan; Spigel, David; Garassino, Marina; Reck, Martin; Senan, Suresh; Naidoo, Jarushka; Rimner, Andreas; Wu, Yi-Long; Gray, Jhanelle; Özgüroğlu, MUSTAFA; Lee, Ki; Cho, Byoung; Kato, Terufumi; De Wit, Maike; Newton, Michael; Wang, Lu; Thiyagarajah, Piruntha; Antonia, Scott

doi:10.1016/j.jtho.2020.12.015

Brief report: Four-year survival with durvalumab after chemoradiotherapy in Stage III NSCLC - an update from the PACIFIC trial.

Faivre-Finn C., Vicente D., Kurata T., Planchard D., Paz-Ares L., Vansteenkiste J. F., ...Daha Fazla

Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, cilt.16, ss.860-867, 2021 (SCI-Expanded, Scopus)

Yayın Türü: Makale / Tam Makale
Cilt numarası: 16
Basım Tarihi: 2021
Doi Numarası: 10.1016/j.jtho.2020.12.015
Dergi Adı: Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus, CINAHL, EMBASE, MEDLINE
Sayfa Sayıları: ss.860-867
Anahtar Kelimeler: Durvalumab, Locally advanced NSCLC, PACIFIC, Overall survival, Progression-free survival, CELL LUNG-CANCER, PHASE-III, CISPLATIN, RADIATION, ETOPOSIDE
İstanbul Üniversitesi-Cerrahpaşa Adresli: Hayır

Özet

Introduction: In the Phase 3, placebo-controlled PACIFIC trial of patients with unresectable, stage III NSCLC without disease progression after concurrent chemoradiotherapy, consolidative durvalumab was associated with significant improvements in the primary end points of overall survival (OS) (hazard ratio [HR] = 0.68; 95% confidence interval [CI]: 0.53-0.87; p = 0.00251; data cutoff, March 22, 2018) and progression-free survival (PFS) (blinded independent central review; Response Evaluation Criteria in Solid Tumors version 1.1) (HR = 0.52; 95% CI: 0.42-65; p < 0.0001; February 13, 2017) with manageable safety. Here, we report updated analyses of OS and PFS, approximately 4 years after the last patient was randomized.